Literature DB >> 25369777

Perturbation of chemical coupling by an endothelial Cx40 mutant attenuates endothelium-dependent vasodilation by KCa channels and elevates blood pressure in mice.

Daniel J Chaston1, Rebecca E Haddock, Lauren Howitt, Susan K Morton, Russell D Brown, Klaus I Matthaei, Caryl E Hill.   

Abstract

Mutant forms of connexin40 (Cx40) exist in the human population and predispose carriers to atrial fibrillation. Since endothelial expression of Cx40 is important for electrical and chemical communication within the arterial wall, carriers of mutant Cx40 proteins may be predisposed to peripheral arterial dysfunction and dysregulation of blood pressure. We have therefore studied mice expressing either a chemically dysfunctional mutant, Cx40T202S, or wild-type Cx40, with native Cx40, specifically in the endothelium. Blood pressure was measured by telemetry under normal conditions and during cardiovascular stress induced by locomotor activity, phenylephrine or nitric oxide blockade (N(ɷ)-nitro-L-arginine methyl ester hydroxide, L-NAME). Blood pressure of Cx40T202STg mice was significantly elevated at night when compared with wild-type or Cx40Tg mice, without change in mean heart rate, pulse pressure or locomotor activity. Analysis over 24 h showed that blood pressure of Cx40T202STg mice was significantly elevated at rest and additionally during locomotor activity. In contrast, neither plasma renin concentration nor pressor responses to phenylephrine or L-NAME were altered, the latter indicating that nitric oxide bioavailability was normal. In isolated, pressurised mesenteric arteries, hyperpolarisation and vasodilation evoked by SKA-31, the selective modulator of SKCa and IKCa channels, was significantly reduced in Cx40T202STg mice, due to attenuation of the SKCa component. Acetylcholine-induced ascending vasodilation in vivo was also significantly attenuated in cremaster muscle arterioles of Cx40T202STg mice, compared to wild-type and Cx40Tg mice. We conclude that endothelial expression of the chemically dysfunctional Cx40T202S reduces peripheral vasodilator capacity mediated by SKCa-dependent hyperpolarisation and also increases blood pressure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25369777     DOI: 10.1007/s00424-014-1640-x

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  43 in total

1.  Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis.

Authors:  Andras Garami; Eszter Pakai; Daniela L Oliveira; Alexandre A Steiner; Samuel P Wanner; M Camila Almeida; Vladimir A Lesnikov; Narender R Gavva; Andrej A Romanovsky
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

2.  Non-linear relationship between hyperpolarisation and relaxation enables long distance propagation of vasodilatation.

Authors:  Stephanie E Wölfle; Daniel J Chaston; Kenichi Goto; Shaun L Sandow; Frank R Edwards; Caryl E Hill
Journal:  J Physiol       Date:  2011-03-21       Impact factor: 5.182

3.  Chronic deficit in nitric oxide elicits oxidative stress and augments T-type calcium-channel contribution to vascular tone of rodent arteries and arterioles.

Authors:  Lauren Howitt; Ivana Y Kuo; Anthie Ellis; Daniel J Chaston; Hee-Sup Shin; Pernille B Hansen; Caryl E Hill
Journal:  Cardiovasc Res       Date:  2013-02-22       Impact factor: 10.787

4.  K+ currents underlying the action of endothelium-derived hyperpolarizing factor in guinea-pig, rat and human blood vessels.

Authors:  H A Coleman; M Tare; H C Parkington
Journal:  J Physiol       Date:  2001-03-01       Impact factor: 5.182

5.  Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in men.

Authors:  Mehran Firouzi; Bart Kok; Wilko Spiering; Andreas Busjahn; Connie R Bezzina; Jan M Ruijter; Bobby P C Koeleman; Maria Schipper; W Antoinette Groenewegen; Habo J Jongsma; Peter W de Leeuw
Journal:  J Hypertens       Date:  2006-02       Impact factor: 4.844

6.  Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries.

Authors:  A T Chaytor; W H Evans; T M Griffith
Journal:  J Physiol       Date:  1997-08-15       Impact factor: 5.182

7.  Rapid endothelial cell-selective loading of connexin 40 antibody blocks endothelium-derived hyperpolarizing factor dilation in rat small mesenteric arteries.

Authors:  Simon Mather; Kim A Dora; Shaun L Sandow; Polly Winter; Christopher J Garland
Journal:  Circ Res       Date:  2005-07-21       Impact factor: 17.367

8.  Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension.

Authors:  Alexander Jobs; Kjestine Schmidt; Volker J Schmidt; Indra Lübkemeier; Toon A B van Veen; Armin Kurtz; Klaus Willecke; Cor de Wit
Journal:  Hypertension       Date:  2012-10-22       Impact factor: 10.190

9.  Spreading vasodilatation in the murine microcirculation: attenuation by oxidative stress-induced change in electromechanical coupling.

Authors:  Lauren Howitt; Daniel J Chaston; Shaun L Sandow; Klaus I Matthaei; Frank R Edwards; Caryl E Hill
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182

10.  Regulation of endothelial-specific transgene expression by the LacI repressor protein in vivo.

Authors:  Susan K Morton; Daniel J Chaston; Brett K Baillie; Caryl E Hill; Klaus I Matthaei
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

View more
  2 in total

1.  Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1/2 pathway.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2016-09-03       Impact factor: 3.657

Review 2.  Endothelium-Dependent Hyperpolarization (EDH) in Hypertension: The Role of Endothelial Ion Channels.

Authors:  Kenichi Goto; Toshio Ohtsubo; Takanari Kitazono
Journal:  Int J Mol Sci       Date:  2018-01-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.